Abstract: An alarm management module (13) is for a wastewater pumping station that includes at least one pump (9a, 9b) arranged for pumping wastewater out of a wastewater pit (1). The alarm management module (13) is configured to process at least one level variable (h) indicative of a filling level of the wastewater pit (1) and at least one capacity variable (p %, P %, C %) indicative of a pumping capacity of the wastewater pumping station. The alarm management module (13) is configured to trigger an intervention alarm only if all of the following conditions are met: a) the at least one level variable (h) is at or above a predetermined alarm level threshold (hm), b) the at least one level variable (h) is increasing, and c) the at least one capacity variable (p %, P %, C %) is below a capacity threshold.

Abstract: A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a method of manufacturing the powdered composition, a method of manufacturing the orally dispensable delivery vehicle, composition for use as a medicament, composition for use in a treatment, method of treatment, and use of a basic ion exchange resin as a stabilizing agent are disclosed.

Abstract: An alarm management module (13) is for a wastewater pumping station that includes at least one pump (9a, 9b) arranged for pumping wastewater out of a wastewater pit (1). The alarm management module (13) is configured to process at least one level variable (h) indicative of a filling level of the wastewater pit (1) and at least one capacity variable (p %, P %, C %) indicative of a pumping capacity of the wastewater pumping station. The alarm management module (13) is configured to trigger an intervention alarm only if all of the following conditions are met: a) the at least one level variable (h) is at or above a predetermined alarm level threshold (hm), b) the at least one level variable (h) is increasing, and c) the at least one capacity variable (p %, P %, C %) is below a capacity threshold.

Abstract: A monitoring module (13) identifies an operating scenario in a wastewater pumping station, with at least one pump (9a, 9b) arranged for pumping wastewater out of a wastewater pit (1) into a pipe (11). The monitoring module (13) is configured to process at least one load-dependent pump variable indicative of how the at least one pump (9a, 9b) operates and at least one model-based pipe parameter indicative of how the wastewater flows through the pipe (11) and/or the at least one pump (9a, 9b). The monitoring module is configured to identify an operating scenario in the wastewater pumping station by selecting an operating scenario from a group of predefined operating scenarios dependent on at least one first criterion that is based on the at least one load-dependent pump variable and at least one second criterion that is based on the at least one model-based pipe parameter.

Abstract: A liquid cannabinoid composition is disclosed, said liquid cannabinoid composition comprising a carrier liquid, and a tetrahydrocannabinolic compound and/or a cannabidiolic compound, wherein at least 95 percent by weight of said tetrahydrocannabinolic compound and/or cannabidiolic compound is present in carboxylated inactive form.

Abstract: A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a method of manufacturing the powdered composition, a method of manufacturing the orally dispensable delivery vehicle, composition for use as a medicament, composition for use in a treatment, method of treatment, and use of a basic ion exchange resin as a stabilizing agent are disclosed.

Abstract: A liquid cannabinoid composition (LCC) is disclosed, said liquid cannabinoid composition (LCC) comprising a vaporizer carrier liquid (VCL), and a tetrahydrocannabinolic compound and/or a cannabidiolic compound, wherein at least 95 percent by weight of said tetrahydrocannabinolic compound and/or cannabidiolic compound is present in acid form. Also, a method of obtaining a liquid cannabinoid composition (LCC), a method of activating a liquid cannabinoid composition (LCC), use of liquid cannabinoid composition (LCC), a cannabinoid container comprising a liquid cannabinoid composition (LCC), and a personal vaporizer comprising such cannabinoid container are disclosed.

Abstract: The present invention relates to a water treatment system comprising a pre-filtering device receiving water, such as waste water, to be treated and providing a filtrate, and a biological treatment device being fluidic connectable to or in fluidic connection with the pre-filtering device for receiving the filtrate from the pre-filtering device. The biological treatment device is adapted to perform a biological treatment of the filtrate and to provide sludge solids. The pre-filtering device is a cake filtration device having a filtration cake wherein the filtration cake is being provided by deposition of solids from the sludge formed in the biological treatment device. A water treatment process employing the system and a method of forming a filter cake are also described.

Abstract: A unit (8) is intended for treating waste water. It includes a well (9) with an inlet conduit connector (21) and with an outlet conduit connector (22) at the outside of the well (9). The unit further includes a connecting conduit (20) inside the well (9). The connecting conduit (20) connects the inlet conduit connector (21) to the outlet conduit connector (22). There is at least one storage tank (13) inside the well (9) for a liquid chemical and a metering pump (18) inside the well (9) for pumping the chemical from the storage tank (13) into the connecting conduit (20). A control device (23) activates the metering pump according to a signal of a sensor (24) which senses a quantity of chemical element in the liquid flowing through the conduit (20).

Abstract: The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation.

Abstract: The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

Abstract: The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

Abstract: The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

Abstract: The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation.

Abstract: The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

Abstract: The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.